Sumatriptan and the other triptan drugs target the serotonin receptor subtypes1B, 1D, and 1F (5-HT 1B/D/F ), and are prescribed widely in the treatment of migraine. An anti-migraine action of triptans has been postulated at multiple targets, within the brain and at both the central and peripheral terminals of trigeminal ''pain-sensory" fibers. However, as triptan receptors are also located on ''pain-sensory" afferents throughout the body, it is surprising that triptans only reduce migraine pain in humans, and experimental cranial pain in animals. Here we tested the hypothesis that sumatriptan can indeed reduce non-cranial, somatic and visceral pain in behavioral models in mice. Because sumatriptan must cross the blood brain barrier to reach somatic afferent terminals in the spinal cord, we compared systemic to direct spinal (intrathecal) sumatriptan. Acute nociceptive thresholds were not altered by sumatriptan pre-treatment, regardless of route. However, in behavioral models of persistent inflammatory pain, we found a profound anti-hyperalgesic action of intrathecal, but not systemic, sumatriptan. By contrast, sumatriptan was completely ineffective in an experimental model of neuropathic pain. The pronounced activity of intrathecal sumatriptan against inflammatory pain in mice raises the possibility that there is a wider spectrum of therapeutic indications for triptans beyond headache.
Introduction
The triptans, which target the serotonin receptor subtypes 1B, 1D, and 1F (5-HT 1B/D/F ), are thought to exert their anti-migraine effects at multiple neural circuits that transmit ''pain" messages. Thus triptans may activate pain-inhibitory control mechanisms within the brain
[4], as well as inhibit the activation of trigeminal sensory neurons, by regulating cerebral blood flow in the periphery and reducing the release of ''pain" neurotransmitters centrally [8, 12, 16, 23, 25, 28, 31, 38] . The latter hypothesis is of particular interest because triptan receptor expression is widespread, found equally among trigeminal sensory afferents and afferents that innervate the rest of the body [37, 44] . As this nonselective distribution is at odds with the prevailing view that triptans have selective actions for migraine/cranial pain [4, 17, 29] , we explored the possibility of an analgesic action of sumatriptan on non-cranial pain, independent of the pain of headache.
We and others previously reported the predominant expression of the 5-HT 1D receptor subtype within a
